EUCTR2004-000113-18-HU进行中（未招募）不适用
A randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy, safety and tolerability of licarbazepine 750-2500 mg/d combined with risperidone in the treatment of manic episodes of bipolar I disorder over 6 weeks
ovartis Hungaria Kft.0 个研究点目标入组 430 人开始时间: 2004年9月6日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 430
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •males and females 18 through 70 years of age;
- •diagnosis of bipolar disorder type I, manic or mixed episode according to DSM-IV criteria (i.e., 296.0, 296.4 or 296.6), including patients with/without psychotic features or with/without a history of rapid cycling;
- •total score of at least 20 on the Young Mania Rating Scale (Y-MRS);
- •need of psychiatric treatment;
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •current DSM-IV Axis-I diagnosis other than bipolar I disorder;
- •history of schizophrenia or schizoaffective disorder;
- •concomitant use of psychoactive medication other than risperidone and lorazepam, whereby the time between the last dose of prior medication and the baseline visit is dependent on the medication;
- •drug dependence during the one month prior to screening. Drug dependence is defined by DSM-IV criteria;
- •positive urine drug screen at screening visit for amphetamines, cocaine, hallucinogens or opiates;
- •history of suicide attempt within the month prior to the screening visit or immediate risk of harm to self or others at the time of screening, as judged by the Investigator;
- •mental retardation (according to DSM-IV criteria);
- •female patients of childbearing potential who are not using effective contraception during the study, are breast feeding, or have a positive pregnancy test (? hCG) at screening or baseline;
- •any non-psychiatric coexistent illness (e.g., diabetes mellitus, hypothyroidism) that has not been maintained in a stable condition for at least 3 months prior to baseline;
- •clinically significant abnormal conditions of the gastrointestinal system, liver, or kidneys, which could result in the possibility of altered absorption, excess accumulation, or impairment of metabolism or excretion of the study drug;
- •twice the upper normal limit at screening and upon repeated measurement for any one of the following laboratory parameters: SGOT, SGPT, LDH, alkaline phosphatase, or bilirubin BUN values ? 30 mg/dL or creatinine clearance < 30 ml/min;
- •any other clinically significant abnormal laboratory findings at screening which remain abnormal upon repeated measurement;
- •any of the following serological findings:
- •- a positive hepatitis A antibody (IgM);
- •- a positive hepatitis B surface antigen (HBsAg);
- •- a positive hepatitis B core antibody (Anti-HBcAb), along with a negative hepatitis B surface antibody
- •(Anti-HBsAb), in the setting of abnormal liver enzymes or recent clinical symptoms of hepatitis (within
- •the last 2 months);
- •current diagnosis or recent past history of epilepsy, major head trauma, or progressive neurological disease (e.g., Parkinson’s disease, ALS);
- •electroconvulsive therapy (ECT) within the one months preceding baseline;
- •any form of psychotherapy within the one month preceding baseline;
研究者
相似试验
进行中（未招募）
1 期
A Study to Evaluate the Safety and Efficacy of RO7123520 as Adjunct Treatment in Patients With Moderately to Severely Active Rheumatoid Arthritis and an Inadequate Response to TNF-a InhibitorsMedDRA version: 20.0Level: PTClassification code 10039073Term: Rheumatoid arthritisSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disordersRheumatoid ArthritisEUCTR2016-002126-36-ESF. Hoffmann-La Roche Ltd204
进行中（未招募）
1 期
Efficacy and safety study evaluating a new sublingual treatment in HDM allergic rhinitisHouse dust mite allergic rhinitisMedDRA version: 18.0Level: LLTClassification code 10001725Term: Allergic rhinitis due to other allergenSystem Organ Class: 100000004855EUCTR2014-004223-46-ESStallergenes S.A.990
进行中（未招募）
不适用
A randomized, double-blind, placebo-controlled, multicenter study of the efficacy and safety of Ritalin® LA in adult patients with childhood-onset ADHDAdult patients with childhood-onset Attention Deficit Hyperactivity DisorderMedDRA version: 12.1Level: LLTClassification code 10003735Term: Attention deficit-hyperactivity disorderMedDRA version: 12.1Level: LLTClassification code 10003736Term: Attention deficit/hyperactivity disorderMedDRA version: 12.1Level: LLTClassification code 10003737Term: Attention deficit/hyperactivity disorder NOSMedDRA version: 12.1Level: PTClassification code 10003736Term: Attention deficit/hyperactivity disorderEUCTR2010-021533-31-DKovartis Pharma Services AG700
进行中（未招募）
1 期
Safety and efficacy of different oral doses of BAY 94-8862 in subjects with type 2 diabetes mellitus and the clinical diagnosis of diabetic nephropathyDiabetic nephropathyMedDRA version: 16.1 Level: PT Classification code 10061835 Term: Diabetic nephropathy System Organ Class: 10038359 - Renal and urinary disordersEUCTR2012-004179-38-NLBayer HealthCare AG823
进行中（未招募）
1 期
A randomized, double-blind, placebo-controlled, multicenter phase III study of RAD001 adjuvant therapy in poor risk patients with Diffuse Large B-Cell Lymphoma (DLBCL) of RAD001 versus matching placebo after patients have achieved complete response with first-line rituximab-chemotherapyDiffuse Large B-Cell LymphomaMedDRA version: 19.0Level: PTClassification code 10012818Term: Diffuse large B-cell lymphomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2008-000498-40-ATovartis Pharma Services AG487